Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis

HIV Clinical Trials

Volumn 18, Issue 1, 2017, Pages 17-27

  Ewald, Hannah ^a   Santini Oliveira, Marilia ^a,b   Bühler, Julian Emanuel ^a   Vuichard, Danielle ^c,d   Schandelmaier, Stefan ^a,d   Stöckle, Marcel ^c   Briel, Matthias ^a,d,e   Bucher, Heiner C ^a   Hemkens, Lars G ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Funda??o Oswaldo Cruz   (Brazil)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antiretroviral experienced; HIV; Meta analysis; Tenofovir

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPID; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ANTIRETROVIRAL THERAPY; ARTICLE; BODY FAT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; EMBASE; ESTIMATED GLOMERULAR FILTRATION RATE; FRACTURE; HEALTH; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; BLOOD; DRUG EFFECTS; FRACTURES, BONE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; LIPID METABOLISM; PUBLISHING; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; FRACTURES, BONE; HIV INFECTIONS; HUMANS; LIPID METABOLISM; LIPIDS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85004019945     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1080/15284336.2016.1261073     Document Type: Article

References (52)

1. European AIDS Clinical Society (EACS). EACS Guidelines Version 8.0–October 2015; 2015. http://www.eacsociety.org/files/guidelines_8_0-english_web.pdf. Accessed July 7, 2016.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 21, 2016.
3. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA. 2016;316(2):191–210.10.1001/jama.2016.8900
4. Abgrall S, Ingle SM, May MT, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013;27(5):803–813.
5. Hemkens LG, Ewald H, Santini-Oliveira M, et al. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients:systematic review and meta-analysis. HIV Clin Trials. 2015;16(5):178–189.10.1179/1945577115Y.0000000004
6. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413–1415.10.1136/bmj.a117
7. HIV Drug Therapy in the Americas Congress 13–15 January 2013, São Paulo Brazil. J Int AIDS Soc. 2013;16(1):1–24.
8. Raghunathan K, Bonavia A, Nathanson BH, et al. Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock. Anesthesiology 2015;123(6):1385–1393.10.1097/ALN.0000000000000861
9. 14th European AIDS Conference 16–19 October 2013. Brussels; 2013. http://www.eacs-conference2013.com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web.pdf.
10. 11th International Congress on Drug Therapy in HIV infection 11–15 November 2012, Glasgow UK. J Int AIDS Soc. 2012;15(4):1–176.
11. XIX International AIDS Conference 22–27 July 2012, Washington, DC, USA. J Int AIDS Soc. 2012;15(3):1–287.
12. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochrane-handbook.org. Accessed March 2011.
13. Nuesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis in randomised controlled trials:meta-epidemiological study. BMJ. 2009;339:b3244.10.1136/bmj.b3244
14. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol. 2005;34(1):79–87.
15. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Internal Med. 1997;127(9):820–826.10.7326/0003-4819-127-9-199711010-00008
16. Loutfy MR, Ackad N, Antoniou T, et al. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen. HIV Clin Trials. 2007;8(5):259–268.10.1310/hct0805-259
17. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens:the HIV STAR study. Antivir Ther. 2012;17(7):1351–1361.10.3851/IMP2443
18. Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in assure, a randomized, open label, non-inferiority trial. PLoS ONE. 2014;9(5):e96187.10.1371/journal.pone.0096187
19. Negredo E, Domingo P, Perez-Alvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density:two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69(12):3368–3371.10.1093/jac/dku300
20. Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control:48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis. 2014;46(1):34–45.10.3109/00365548.2013.840920
21. Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression:a randomized multicenter trial. PLoS ONE. 2013;8(8):e73639.10.1371/journal.pone.0073639
22. Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE. 2012;7(6):e38377.10.1371/journal.pone.0038377
23. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir‐emtricitabine or abacavir‐lamivudine:a randomized, 96‐week trial. Clin Infect Dis. 2009;49(10):1591–1601.10.1086/599193
24. Curran A, Martinez E, Podzamczer D, et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine:a substudy of the BICOMBO trial. Antiviral Ther. 2012;17(4):711–718.10.3851/IMP2081
25. Martinez E, Arranz JA, Podzamczer D, et al. Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/ emtricitabine (TDF/FTC):3-year results of the BICOMBO study. Paper presented at Conference:10th International Congress on Drug Therapy in HIV Infection Glasgow United Kingdom. Var.Pagings. 2010.
26. Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression. JAIDS. 2009;51(3):290–297.10.1097/QAI.0b013e3181aa12d5
27. Saumoy M, Ordoñez-Llanos J, Martínez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antiviral Ther. 2011;16(4):459–468.10.3851/IMP1785
28. Cohen C, Green J, Olivet H, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. J Int AIDS Soc. 2012;15(4):18279.
29. Martínez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24(3):F1–F9.10.1097/QAD.0b013e32833562c5
30. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients:results from a 48-week, randomized, double-blind study. AIDS. 2002;16(9):1257–1263.10.1097/00002030-200206140-00008
31. Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antiviral Ther. 2007;12:407–415.
32. Koulla-Shiro S, Le Moing V, Ndour C, et al. Randomized comparison of three second line art regimens in Africa:the 2 lady/ANRS/EDCTP study. Paper presented at:Conference on Retroviruses and Opportunistic Infections (abstract and poster 541LB). 2014.
33. Cooper V, Moyle GJ, Fisher M, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care. 2011;23(6):705–713.10.1080/09540121.2010.534433
34. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. JAIDS. 2009;51(5):562–568.10.1097/QAI.0b013e3181ae2eb9
35. Campo R, DeJesus E, Bredeek UF, et al. SWIFT:prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56(11):1637–1645.10.1093/cid/cis1203
36. Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLOS ONE. 2015;10(2):e0116297.10.1371/journal.pone.0116297
37. Orkin C, Moyle G, Fisher M, Wang H, Ewan J, ROCKET I Study Group. Switching from Kivexa [KVX] ABC/3TC + Efavirenz [EFV] to Atripla [ATR] (EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects:preliminary results of a 24-week randomized study. Paper presented at:16th Annual Conference of the British HIV Association; Apr 21–23, 2010.
38. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol:effect on lipid profiles. Antivir Ther. 2012;17(6):1011–1020.10.3851/IMP2305
39. Calza L, Manfredi R, Colangeli V, et al. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care and STDs. 2009;23(9):691–697.10.1089/apc.2009.0039
40. Valantin MA, Bittar R, De Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+ emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010;65(3):556–561.10.1093/jac/dkp462
41. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043–2050.10.1097/01.aids.0000247574.33998.03
42. McComsey GA, O’Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy:randomized study of uridine supplementation or switch to tenofovir. Antivir Ther. 2012;17(2):347–353.
43. Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the prepare study. J Clin Endocrinol Metab. 2013;98(4):1659–1666.10.1210/jc.2012-3686
44. Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25(17):2149–2155.10.1097/QAD.0b013e32834bba87
45. Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21(7):813–823.10.1097/QAD.0b013e32805e8753
46. Ribera E, Larrousse M, Curran A, et al. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy:the RECOMB study. HIV Med. 2013;14(6):327–336.10.1111/hiv.2013.14.issue-6
47. Rasmussen TA, Tolstrup M, Melchjorsen J, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011;11(1):267.10.1186/1471-2334-11-267
48. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE. 2012;7(3):e32445.10.1371/journal.pone.0032445
49. Ioannidis JPA, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses:breadth, timing, and depth of the evidence. BMJ. 2010;341:c4875.
50. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials:an extension of the CONSORT statement. Ann Internal Med. 2004;141(10):781–788.10.7326/0003-4819-141-10-200411160-00009
51. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10(1):1–12.10.1310/hct1001-1
52. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383(9913):267–276.10.1016/S0140-6736(13)62228-X